Pfizer (NYSE: PFE) shares received a price objective of $42 from the analyst of Royal Canada Bank. The company received a rating of ‘neutral’ for their stock, indicating a potential 14.07% upside from earlier close.
On Tuesday, Pfizer started from $36.82 in the stock market with the market cap being $204.66B. Their lowest in 52 weeks is $27.88 while the highest is $43.08. Their current, quick, and leverage ratio is 1.42, 1.16, and 0.78. Their 50-day rolling average price is $38.36 while the 200 day is $36.86.
According to the 27th October report, the company has a quarterly EPS earning of $0.72 that topped the $0.71 consensus estimate by almost $0.01. Their net margin was 28.80% with a 25.11% equity return. Their quarterly revenue was $12.13B compared to the $12.30B estimates.
Undertakings Of PFE Stock
Atlantic Securities decreased the price objective of PFE stock to $39 from $44 along with the rating to ‘neutral’ from ‘overweight’. TheStreet raised the rating to ‘b-’ from ‘c+’. BidaskClub demoted the rating for Pfizer to ‘sell’ from ‘hold’. JPMorgan Chase&Co. issued a price objective of $36 to the company with a rating of ‘neutral’. The company currently has the consensus ‘hold’ recommendation with a $39.87 price objective.
An important shareholder purchased 1,200,000 PFE shares at $10 EPS worth $12,000,000. 0.08% of PFE stock is owned by insiders.
LVZ Advisors acquired new holdings in Pfizer in Q3 that is priced at $301,000. Vista Pvt Partners raised their holdings by almost 7% in Q3 and own shares worth $310,000. HM Payson&Co increased their stake by approximately 4.8% in Q3, owning $59,889,000 worth of shares. Trust Co lifted their position by almost 150.3% in Q3, owning shares priced at $623,000. Burney Co increased its holdings by almost 1.3% in Q3, owning shares worth $7,399,000. 69.08% of PFE stock is owned by hedge funds and institutional investors.
